R&D Trends

CHOP launches Roberts Collaborative for Genetics and Individualized Medicine

Monday, September 26, 2016

The Children’s Hospital of Philadelphia (CHOP) has announced the creation of the Roberts Collaborative for Genetics and Individualized Medicine at CHOP. The $50 million Roberts Collaborative will position CHOP at the forefront of pediatric genetics research and will take a multidisciplinary approach toward diagnostics, clinical management, consulting, therapeutics and research driven by the power of genetics. The Roberts family is the principal source of external funding for this initiative, with a $25 million gift that will facilitate the integration of all clinical departments, divisions and centers for the care of pediatric patients, as well as advance a relentless pursuit of breakthrough cures for childhood disease.

[Read More]

GE Healthcare launches $50M global health startup accelerator

Monday, September 26, 2016

GE Healthcare, the $18 billion healthcare technology division of GE, launched the company’s first healthcare accelerator, five.eight, aimed at improving healthcare outcomes for the world’s developing economies. The accelerator will target global health startups with a vision to improve healthcare quality and accessibility in developing or low-resource settings—from education and training to disruptive, low-cost technologies and digital applications.

[Read More]

NIH funds research network focused on HIV-infected youth

Monday, September 26, 2016

The NIH has awarded funding for a research network devoted to the health and well-being of adolescents and young adults with HIV or at risk for HIV infection. The awards, up to $24 million in 2016, provide for three research centers and a data coordinating center that will make up the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN).

[Read More]

Bayer, Evotec partner on kidney diseases treatments

Wednesday, September 21, 2016

Bayer and Evotec have entered into a five-year, multi-target research partnership to develop multiple clinical candidates for the treatment of kidney diseases such as chronic kidney disease in diabetes patients. Both companies will contribute novel drug targets and a comprehensive set of high-quality technology platforms to jointly develop innovative treatment options for these severe conditions. The partners will share responsibilities during preclinical development of potential clinical candidates.

[Read More]

Report: Osteoarthritis space set to approach $10.5B by 2024

Tuesday, September 20, 2016

The osteoarthritis market across the seven major markets of the U.S., France, Germany, Italy, Spain, the U.K., and Japan is forecast to more than treble from $3.25 billion in 2014 to $10.49 billion by 2024, representing a compound annual growth rate of 17.8%, according to research and consulting firm GlobalData.

[Read More]

Cystic Fibrosis Foundation opens research lab

Tuesday, September 20, 2016

The Cystic Fibrosis Foundation has announced the official opening of a new, one-of-a kind research facility in Lexington, Massachusetts. Operated by Cystic Fibrosis Foundation Therapeutics (CFFT), an affiliate of the CF Foundation, the lab is designed to identify and test potential therapies for rare and common mutations of cystic fibrosis, with the ultimate goal of bringing new treatments to people living with the disease.

[Read More]

ORIEN Cancer Initiative, HudsonAlpha collaborate on personalized cancer therapies

Wednesday, September 14, 2016

The Oncology Research Information Exchange Network (ORIEN), an alliance of cancer centers throughout the U.S., and HudsonAlpha Institute of Biotechnology, a nonprofit research institute, have announced a new collaboration to advance cancer research and care. Under the agreement, HudsonAlpha will provide genomic sequencing services for the ORIEN Avatar Research Program. The program allows the nation’s leading cancer centers to optimize and enable novel treatments and clinical trials, which could have the potential to impact millions of patients worldwide.

[Read More]

Fate Therapeutics, Memorial Sloan-Kettering partner on T-Cell Immunotherapies

Tuesday, September 13, 2016

Fate Therapeutics, a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, has announced a partnership with Memorial Sloan-Kettering Cancer Center for the development of off-the-shelf T-cell product candidates using engineered pluripotent cell lines. Research and development activities under the multi-year collaboration will be led by Michel Sadelain, M.D., Ph.D., director of the Center for Cell Engineering and the Stephen and Barbara Friedman Chair at Memorial Sloan-Kettering Cancer Center.

[Read More]